Taxane Response Markers References

Taxane sensitivity: BRCA1

Quinn, J. E., C. R. James, et al. (2007). "BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy." Clin Cancer Res 13(24): 7413-7420.

Boukovinas, I., C. Papadaki, et al. (2008). "Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients." PLoS One 3(11): e3695.

Su, C., S. Zhou, et al. (2010). "ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer." Med Oncol.

Papadaki, C., E. Tsaroucha, et al. (2011). "Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer." Br J Cancer 104(2): 316-323.

Taxane sensitivity: TLE3

Samimi, G., W.K. Huh (2011). "TLE3 expression is associated with sensitivity to taxane treatment in ovarian carcinoma." CancerEpidemiol. Biomarkers Prev. 21(2):273-9.

Kulkarni, S.A., Hicks, D.G., Watroba, N.L., Murekeyisoni, C., Hwang, H., Khoury, T., Beck, R.A., Ring, B.Z., Estopinal, N.C., Schreeder, M.T., et al. (2009). TLE3 as a candidate biomarker of response to taxane therapy. Breast Cancer Res 11, R17.

Nab-paclitaxel sensitivity: SPARC

Desai, N., V. Trieu, et al. (2009). "SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients." Transl Oncol 2(2): 59-64.

Taxane resistance: TUBB3

Mozzetti, S., C. Ferlini, et al. (2005). "Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients." Clin Cancer Res 11(1): 298-305.

Ohishi, Y., Y. Oda, et al. (2007). "Expression of beta-tubulin isotypes in human primary ovarian carcinoma." Gynecol Oncol 105(3): 586-592.

Umezu, T., K. Shibata, et al. (2008). "Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin." Int J Gynecol Pathol 27(2): 207-212.

Ferrandina, G., G. F. Zannoni, et al. (2006). "Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients." Clin Cancer Res 12(9): 2774-2779.

Taxane resistance: PGP

Kamazawa, S., J. Kigawa, et al. (2002). "Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer." Gynecol Oncol 86(2): 171-176.

Goto, T., M. Takano, et al. (2006). "Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers." Oncol Rep 15(5): 1265-1271.

Naniwa, J., J. Kigawa, et al. (2007). "Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer." Int J Gynecol Cancer 17(1): 76-82.

Penson, R. T., E. Oliva, et al. (2004). "Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples." Gynecol Oncol 93(1): 98-106.

Yakirevich, E., E. Sabo, et al. (2006). "Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas." Gynecol Oncol 100(1): 152-159.

Taxane resistance: ER

Formenti, S. C., D. Spicer, et al. (2002). "Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer." Int J Radiat Oncol Biol Phys 52(2): 397-405.

Ogston, K. N., I. D. Miller, et al. (2004). "Can patients' likelihood of benefiting from primary chemotherapy for breast cancer be predicted before commencement of treatment?" Breast Cancer Res Treat 86(2): 181-189.

Kim, S. J., Y. Miyoshi, et al. (2005). "High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer." Clin Cancer Res 11(23): 8425-8430.

Lee, K. H., S. A. Im, et al. (2007). "Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy." BMC Cancer 7: 63.

Warm, M., R. Kates, et al. (2007). "Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancer." Anticancer Res 27(2): 1031-1038.

Zhou, B., D. Q. Yang, et al. (2008). "Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma." Chin Med J (Engl) 121(5): 387-391.

Jeong, J. H., S. Y. Jung, et al. (2010). "Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer." Invest New Drugs.

Taxane resistance: Survivin

Duan, Z., E. J. Weinstein, et al. (2008). "Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer." Mol Cancer Ther 7(8): 2377-2385.

Zaffaroni, N., M. Pennati, et al. (2002). "Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer." Cell Mol Life Sci 59(8): 1406-1412.